{"id":2011,"date":"2023-01-26T21:43:53","date_gmt":"2023-01-26T18:43:53","guid":{"rendered":"https:\/\/www.sightsciences.com\/us\/?p=1770"},"modified":"2024-05-28T12:45:49","modified_gmt":"2024-05-28T09:45:49","slug":"sight-sciences-announces-1000th-tearcare-customer-installation","status":"publish","type":"post","link":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/","title":{"rendered":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation"},"content":{"rendered":"
\n

\nPDF Version<\/a>
\n<\/span><\/div>\n
\n

Over 1,000 Professional Eye Care Practices Have integrated the
\nTearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland
\nDysfunction (MGD)<\/h3>\n

MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences,
\nInc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company
\nfocused on creating innovative solutions intended to transform care and improve
\npatients\u2019 lives, announced today the 1,000th<\/sup> installation of its TearCare\u00ae
\nSystem. The TearCare\u00ae System is FDA cleared and indicated for the application of
\nlocalized heat therapy in adult patients with evaporative dry eye disease due to
\nmeibomian gland dysfunction, when used in conjunction with manual expression of the
\nmeibomian glands.<\/p>\n

In 2019 Sight Sciences commercialized the TearCare\u00ae System with the
\nknowledge that doctors, and patients were seeking improvements beyond those provided by
\ncurrent over the counter, prescription pharmaceutical, or in-office treatments for dry
\neye. Desired improvements included faster action, enduring results and, in the case of
\nin-office treatment, a price point allowing more practices to equip their offices.
\nImmediately following launch, Sight Sciences took the first step required to obtain
\naccess to coverage and payment for dry eye sufferers when the American Medical
\nAssociation (AMA) granted a temporary procedural code specifically describing the open
\neye TearCare\u00ae procedure. In 2021, on the heels of publishing compelling signs and
\nsymptoms clinical results from its first large randomized controlled clinical trial
\n(RCT), OLYMPIA, in the leading ocular surface journal Cornea, the company announced the
\ninitiation of its second pivotal RCT, the SAHARA study, intended to assist payors in
\nproviding fair patient access to the interventional TearCare dry eye procedure. Sahara
\nis a large randomized controlled clinical trial designed to provide a robust body of
\nevidence comparing the long-term efficacy of the TearCare\u00ae System to a traditional,
\ndaily, prescription pharmaceutical treatment regimen for dry eye. The company expects to
\nbegin readout and publishing of the data from SAHARA later this year and continuing into
\n2024. The company intends to use the data to support the case for appropriate coverage
\nand payment by third party payers to help drive patient access to care for dry eye
\ndisease due to MGD.<\/p>\n

Total Eye Care of Long Island, N.Y., was the 1000TH practice to install
\nthe TearCare\u00ae System. Stephanie K. Becker, MD, CEO & noted dry eye specialist,
\ncommented that \u201cimpressive clinical study results, device footprint with a reasonable
\ncapital investment, along with Sight Sciences’ commitment to pursue appropriate
\ninsurance coverage and fair payment all combined in the decision to add the TearCare\u00ae
\nSystem to our dry eye treatment armamentarium. We are pleased to offer TearCare\u00ae to
\nindicated dry eye patients.\u201d<\/p>\n

\u201cWe are thrilled that over 1,000 eye care practices have chosen the
\nTearCare\u00ae System to treat dry eye caused by MGD,\u201d said Paul Badawi, co-founder, and
\nChief Executive Officer of Sight Sciences. \u201cWe designed TearCare\u00ae to treat the
\nunderlying cause of MGD and restore production of healthy tears. The over 1,000 votes of
\nconfidence that we have received from eye doctors across the United States along with
\nour outstanding clinical and real-world outcomes, demonstrate the increasing importance
\nand acceptance of effective interventional dry eye treatment. We are particularly proud
\nto have an ophthalmologist of Dr. Becker\u2019s clinical reputation and expertise represent
\nthis milestone occasion.\u201d<\/p>\n

About Sight Sciences<\/strong>
\nSight Sciences is an eyecare technology company focused on developing and
\ncommercializing innovative solutions intended to transform care and improve patients\u2019
\nlives. Using minimally invasive or non-invasive approaches to target the underlying
\ncauses of the world\u2019s most prevalent eye diseases, Sight Sciences seeks to create more
\neffective treatment paradigms that enhance patient care and supplant conventional
\noutdated approaches. The Company\u2019s OMNI\u00ae Surgical System is a minimally invasive
\nglaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult
\npatients with primary open-angle glaucoma (POAG), the world\u2019s leading cause of
\nirreversible blindness. The Company\u2019s TearCare\u00ae System is 510(k) cleared for the
\napplication of localized heat therapy in adult patients with evaporative dry eye disease
\ndue to meibomian gland dysfunction (MGD), enabling office-based clearance of gland
\nobstructions by physicians to address the leading cause of dry eye disease. The
\nCompany\u2019s SION\u2122 Surgical Instrument is a manually operated device used in ophthalmic
\nsurgical procedures to excise trabecular meshwork.<\/p>\n

About the TearCare\u00ae System<\/strong>
\nThe TearCare\u00ae System is FDA cleared and indicated for the application of localized heat
\ntherapy in adult patients with evaporative dry eye disease due to meibomian gland
\ndysfunction, when used in conjunction with manual expression of the meibomian glands.
\nThe TearCare\u00ae System is the only device designed to evacuate obstructed meibomian glands
\nwhile harnessing a natural blink experience. The system is comprised of single-use,
\nuniversally fitting SmartLids\u2122 which are placed on the eyelids to deliver \u201cintelligent
\ntherapeutic heat\u201d safely and effectively. The portable SmartHub\u2122 communicates directly
\nwith the SmartLids to precisely control the amount of phase transition heating and the
\nduration of treatment. After 15 minutes of therapeutic heat, the Clearance Assistant
\nforceps allows the ECP to control expression of the stagnant, obstructed meibum expertly
\nand precisely by targeting individual meibomian glands while obtaining full visual
\nconfirmation of the success of this personalized treatment.
\nFor more information, visit www.sightsciences.com<\/a>.<\/p>\n

OMNI\u00ae and TearCare\u00ae are registered trademarks of Sight Sciences.
\nSION\u2122 is a trademark of Sight Sciences.
\n\u00a9 2023 Sight Sciences. All rights reserved.<\/p>\n

Forward-Looking Statements<\/strong>
\nThis press release, together with other statements and information publicly disseminated
\nby the Company, contains certain forward-looking statements within the meaning of
\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
\nExchange Act of 1934, as amended. The Company intends such forward-looking statements to
\nbe covered by the safe harbor provisions for forward-looking statements contained in the
\nPrivate Securities Litigation Reform Act of 1995. Forward-looking statements include
\ninformation concerning status of the Company’s SAHARA clinical trial and anticipated
\ntiming and use of SAHARA clinical trial results. These statements often include words
\nsuch as \u201canticipate,\u201d \u201cexpect,\u201d \u201csuggests,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cestimates,\u201d
\n\u201ctargets,\u201d \u201cprojects,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cforecast\u201d and other
\nsimilar expressions. Management bases these forward-looking statements on its current
\nexpectations, plans and assumptions affecting the Company\u2019s business and industry, as
\nwell as our perceptions of historical trends, current conditions, expected future
\ndevelopments and other factors we believe are appropriate under the circumstances at
\nsuch time. Although we believe that these forward-looking statements are based on
\nreasonable assumptions at the time they are made, you should be aware that many factors
\ncould affect our business, results of operations and financial condition and could cause
\nactual results to differ materially from those expressed in the forward-looking
\nstatements. These statements are not guarantees of future performance or results. The
\nforward-looking statements are subject to and involve risks, uncertainties and
\nassumptions, and you should not place undue reliance on these forward-looking
\nstatements. Some of the risks and uncertainties that may cause actual results to
\nmaterially differ from those expressed or implied by these forward-looking statements
\nare discussed under the caption \u201cRisk Factors\u201d in the Company\u2019s filings with the U.S.
\nSecurities and Exchange Commission, as may be updated from time to time in subsequent
\nfilings. These cautionary statements should not be construed by you to be exhaustive and
\nare made only as of the date of this press release. We undertake no obligation to update
\nor revise any forward-looking statements, whether as a result of new information, future
\nevents or otherwise, except as required by applicable law.<\/p>\n

Media contact <\/strong>
\nHannah Jenkins
\nRHMM Inc.
\npr@SightSciences.com<\/p>\n

Investor contact:<\/strong>
\nPhilip Taylor
\nGilmartin Group
\n415.937.5406
\nInvestor.Relations@Sightsciences.com<\/p>\n

\"\"<\/p>\n<\/div>\n<\/article>\n","protected":false},"excerpt":{"rendered":"

PDF Version Over 1,000 Professional Eye Care Practices Have integrated the TearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company focused on creating innovative solutions intended […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6,4],"tags":[],"class_list":["post-2011","post","type-post","status-publish","format-standard","hentry","category-news","category-tearcare"],"acf":[],"yoast_head":"\nSight Sciences Announces 1,000th TearCare\u00ae Customer Installation - United States<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation\" \/>\n<meta property=\"og:description\" content=\"PDF Version Over 1,000 Professional Eye Care Practices Have integrated the TearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company focused on creating innovative solutions intended […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-26T18:43:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-28T09:45:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png\" \/>\n<meta name=\"author\" content=\"admin-dev\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin-dev\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\"},\"author\":{\"name\":\"admin-dev\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/88f84507b2364aa1168168756f61f091\"},\"headline\":\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation\",\"datePublished\":\"2023-01-26T18:43:53+00:00\",\"dateModified\":\"2024-05-28T09:45:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\"},\"wordCount\":1250,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"articleSection\":[\"News\",\"TearCare\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\",\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\",\"name\":\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - United States\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"datePublished\":\"2023-01-26T18:43:53+00:00\",\"dateModified\":\"2024-05-28T09:45:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/88f84507b2364aa1168168756f61f091\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"contentUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/88f84507b2364aa1168168756f61f091\",\"name\":\"admin-dev\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"caption\":\"admin-dev\"},\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/author\\\/admin-dev\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - United States","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/","og_locale":"en_US","og_type":"article","og_title":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation","og_description":"PDF Version Over 1,000 Professional Eye Care Practices Have integrated the TearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company focused on creating innovative solutions intended […]","og_url":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/","og_site_name":"United States","article_published_time":"2023-01-26T18:43:53+00:00","article_modified_time":"2024-05-28T09:45:49+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","type":"","width":"","height":""}],"author":"admin-dev","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin-dev","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#article","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/"},"author":{"name":"admin-dev","@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/88f84507b2364aa1168168756f61f091"},"headline":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation","datePublished":"2023-01-26T18:43:53+00:00","dateModified":"2024-05-28T09:45:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/"},"wordCount":1250,"commentCount":0,"image":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage"},"thumbnailUrl":"https:\/\/ml.globenewswire.com\/media\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","articleSection":["News","TearCare"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/","url":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/","name":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - United States","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage"},"image":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage"},"thumbnailUrl":"https:\/\/ml.globenewswire.com\/media\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","datePublished":"2023-01-26T18:43:53+00:00","dateModified":"2024-05-28T09:45:49+00:00","author":{"@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/88f84507b2364aa1168168756f61f091"},"breadcrumb":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage","url":"https:\/\/ml.globenewswire.com\/media\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","contentUrl":"https:\/\/ml.globenewswire.com\/media\/NjZlN2RiOWYtYjE5OC00NWViLWJhNDAtNmE3OGM4OTVjODU3LTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-1000th-tearcare-customer-installation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sightsciences.com\/us\/"},{"@type":"ListItem","position":2,"name":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation"}]},{"@type":"WebSite","@id":"https:\/\/www.sightsciences.com\/us\/#website","url":"https:\/\/www.sightsciences.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sightsciences.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/88f84507b2364aa1168168756f61f091","name":"admin-dev","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","caption":"admin-dev"},"url":"https:\/\/www.sightsciences.com\/us\/author\/admin-dev\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts\/2011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/comments?post=2011"}],"version-history":[{"count":0,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts\/2011\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/media?parent=2011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/categories?post=2011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/tags?post=2011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}